

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

RE-DESIGNATION OF DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Purapharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Cheong Shin Keong (“**Mr. Cheong**”) has been re-designated from an executive Director to a non-executive Director of the Company with effect from 28 June 2021. The biographical information of Mr. Cheong is as follows:

Mr. Cheong was appointed as non-executive Director on 24 March 2020 and re-designated as executive Director on 1 September 2020. Mr. Cheong is an independent non-executive director of Bossini International Holdings Limited (stock code: 592) since September 2017, a company listed on the Stock Exchange, and from January 2015 to January 2020 was an executive director of Television Broadcasts Limited (stock code: 511), a company listed on the Main Board of the Stock Exchange. Mr. Cheong joined Television Broadcasts Limited as controller, marketing and sales in March 1989 and assumed the duties of general manager in April 2004. Mr. Cheong has extensive experience in the advertising and marketing industry and contributes actively to the professional development of marketing in Hong Kong through leading marketing industry bodies. He is a Fellow and Deputy Chairman of the Hong Kong Management Association as well as a Fellow and the former president of the Hong Kong Regional Board of the Chartered Institute of Marketing.

Save as disclosed above, Mr. Cheong (i) has not held any directorships in any public listed companies, whether in Hong Kong or overseas, during the last three years; (ii) does not hold any other positions in the Company and its subsidiaries; and (iii) does not have any other relationship with any Directors, senior management or substantial or controlling shareholders of the Company.

As at the date of this announcement, Mr. Cheong is taken to be interested in 4,146,665 shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)), representing approximately 1.05% of the issued share capital of the Company.

In respect of the re-designation of Mr. Cheong, Mr. Cheong has entered into a letter of appointment with the Company, taking effect from 28 June 2021 until 31 March 2022. Mr. Cheong is subject to retirement by rotation and is eligible for re-election at the annual general meeting in accordance with the Articles of Association of the Company (the “Articles”).

Upon the recommendation of the remuneration committee of the Board, Mr. Cheong will be entitled to HK\$50,000 per quarter payable in arrears at the end of March, June, September and December of each year, and the emoluments were reviewed and approved by the executive Directors with reference to market conditions, his duties and responsibilities, the Group’s remuneration policy and the Articles.

Save as disclosed above, there is no other information which is discloseable pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange and there are no other matters relating to the re-designation of Mr. Cheong that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to acknowledge the contributions of Mr. Cheong to the Board as an executive Director with the deepest gratitude.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and executive Director

Hong Kong, 28 June 2021

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; the non-executive Directors of the Company are Mr. Chow, Stanley and Mr. Cheong Shin Keong; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.